

Suven Life Sciences Announces Clinical and Preclinical Presentations at the Alzheimer's Association International Conference (AAIC) 2024 in Philadelphia, USA.

HYDERABAD, INDIA (July 29, 2024), Suven Life Sciences, a clinical stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, announces several presentations at the Alzheimer's Association International Conference (AAIC®) 2024 taking place in Philadelphia, USA during 28 July – 01 Aug, 2024. AAIC is the largest and most influential International conference dedicated to advancing science related to Dementia and associated disorders.

These presentations will highlight study design of Phase-3 global clinical trial of Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type and preclinical data of Muscarinic M1 Positive Allosteric Modulator (M1 PAM) SUVN-I7016031, and Muscarinic M4 Positive Allosteric Modulator (M4 PAM) SUVN-L3307032.

Details of the presentations:

- **28-July-2024:** SUVN-L3307032, A Positive Allosteric Modulator (PAM) at Muscarinic M4 Receptor for the Treatment of Neuropsychiatric Symptoms
Session: Clinical Manifestations, Neuropsychiatry and Behavioral Neurology.
- **31-July-2024:** Masupirdine (SUVN-502): Phase-3 Study for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer's Type, an Update
Session: Drug Development, Clinical.
- **31-July-2024:** Efficacy of a Muscarinic (M1) Positive Allosteric Modulator, SUVN-I7016031 in Animal Models of Dementia
Session: Drug Development, Pre-clinical.

Team of scientists from Suven will meet several Principal Investigators at AAIC-2024. The meeting aims to discuss the progress, challenges and future directions of Masupirdine Phase-3 global study for the potential treatment of agitation in patients with dementia of the Alzheimer's type.

Suven is showcasing its CNS focused innovations and comprehensive summaries of clinical candidates at exhibit booth # 1241.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

About Suven Life Sciences (“Suven”): Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer’s disease (AD), sleep disorders, major depressive disorders (MDD), Parkinson’s disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 7 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (phase-2 study completed; pivotal phase-3 study in planning); Ropanicant (SUVN-911) for MDD (phase-2 study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (phase-2 study in planning), SUVN-I6107 for dementia in PD (phase-1 study initiated) and 2 other compounds in early stages of clinical development. In addition to these clinical assets, we have 6 projects in research pipeline across multiple potential indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website at <http://www.suven.com>

Risk Statement: Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com